Department of Neurology, The Second Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
Department of Hematology, The First Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
Int J Mol Med. 2021 Mar;47(3). doi: 10.3892/ijmm.2021.4854. Epub 2021 Jan 15.
During the coronavirus disease 2019 (COVID‑19) pandemic, some patients with severe COVID‑19 exhibited complications such as acute ischemic stroke (AIS), which was closely associated with a poor prognosis. These patients often had an abnormal coagulation, namely, elevated levels of D‑dimer and fibrinogen, and a low platelet count. Certain studies have suggested that COVID‑19 induces AIS by promoting hypercoagulability. Nevertheless, the exact mechanisms through which COVID‑19 leads to a hypercoagulable state in infected patients remain unclear. Understanding the underlying mechanisms of hypercoagulability is of utmost importance for the effective treatment of these patients. The present review aims to summarize the current status of research on COVID‑19, hypercoagulability and ischemic stroke. The present review also aimed to shed light into the underlying mechanisms through which COVID‑19 induces hypercoagulability, and to provide therapies for different mechanisms for the more effective treatment of patients with COVID‑19 with ischemic stroke and prevent AIS during the COVID‑19 pandemic.
在 2019 冠状病毒病（COVID-19）大流行期间，一些重症 COVID-19 患者出现了并发症，如急性缺血性脑卒中（AIS），这与预后不良密切相关。这些患者通常存在凝血异常，即 D-二聚体和纤维蛋白原水平升高，血小板计数降低。一些研究表明，COVID-19 通过促进高凝状态诱导 AIS。然而，COVID-19 导致感染患者高凝状态的确切机制仍不清楚。了解高凝状态的潜在机制对于这些患者的有效治疗至关重要。本综述旨在总结 COVID-19、高凝状态和缺血性脑卒中的研究现状。本综述还旨在探讨 COVID-19 诱导高凝状态的潜在机制，并为不同机制提供治疗方法，以更有效地治疗 COVID-19 合并缺血性脑卒中的患者，并在 COVID-19 大流行期间预防 AIS。
